EN DE
Watch Vikas Lifecare Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Vikas Lifecare Limited (VIKASLIFE) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Vikas Lifecare Limited stock ₹0.97, price ₹1.17, that is 17.4% below the price, quality 57 out of 100. Rating: overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive IN · ISIN INE161L01027

VL Vikas Lifecare Limited logo Thin data Nov 13, 2026

Vikas Lifecare Limited

VIKASLIFE · NSE

Cheap enough by our rule and solid company, but falling price: meets 2 of 3 rules.

Get notified free when this changes
Healthy Growth (revenue 5y +46.1 %/yr in INR) 
Low debt 
Generates free cash flow 
Ranks above peers (7/11) 
Revenue last quarter +25% vs. a year ago. 
Quality 57/100 
Peak profit dampened: ₹2.76 → ₹0.9660 
Fair value ₹0.9660 · Overvalued 
Falling price (downtrend) 
Loss-making · 3.7% net margin (TTM) · excl. one-off gain FY2026 -24.4% 
Narrow moat 30/100
Thin data 
⟳ Cyclical
Watch Vikas Lifecare Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹7.90 ₹1.06 Fair Value ₹0.9660 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

60‑month range ₹1.06 – ₹7.90 · fair‑value band ₹0.6860 – ₹1.26 · the ₹1.17 price screens above the ₹0.9660 fair value. As of Nov 13, 2026.

Follow Vikas Lifecare in your weekly email

Every Wednesday you see whether Vikas Lifecare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vikas Lifecare Limited engages in manufacturing and trading of polymers, chemicals, iron and steel, and plastic products in India and Ghana.

Show moreShow less

The company operates through Real Estate Division; Trading & Manufacturing Division -Agro; Trading & Manufacturing Division -Polymers; and Trading Division -Infrastructure segments.

It offers various polymer compounds, including PE compounds, PVC compounds, V blend SOE compounds, polypropylene compounds, and thermo plastic rubber (TPR) compounds.

The company is involved in developing smart products comprising smart gas and water meters, and power distribution solutions; supplying of food grade piping systems for drinking water; infrastructure products consisting of drinking water pipes, fittings, and bars; trading of agro products, including rice and pulses; dealing in raw and finished cashew nuts, dry fruits, and other premium consumer products.

In addition, it engages in research and development of horticultural, cultivation, and preservation and storage of agro products; aluminium foils; and processed food products. Further, the company is involved in the real estate activities. It also exports its products.

The company was formerly known as Vikas Multicorp Limited and changed its name to Vikas Lifecare Limited in April 2021. Vikas Lifecare Limited was incorporated in 1995 and is based in Delhi, India.

Stock analysis

Vikas Lifecare Limited (VIKASLIFE) currently trades at ₹1.17, while our model-based Fair Value estimate is ₹0.9660, 17% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹2.76 per share, and 16 of the 17 models we run sit above the ₹1.17 price.

Bear case: the Asset-Based group reads lowest at ₹0.2800, and 1 of the 17 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹0.6860 (bear) to ₹1.26 (bull), the price of ₹1.17 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Consumer Defensive sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Vikas Lifecare Limited reported revenue of ₹5.0B in FY2026 versus ₹3.0B in FY2022, a compound +13.5%/yr. Reported net income was ₹184M in FY2026, compounding −10.5%/yr from FY2022.

Key figures

Market cap ₹2.2B (≈ $23.1M) Micro · P/S ratio 0.42 · EPS (TTM) ₹0.1000 · Net margin 3.7% · Return on equity 3.4% · Return on assets (EBIT) −0.6% (5-year average) · Operating margin −16.4% · Revenue (TTM) ₹5.0B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (medium confidence).

What moves the price

The share trades about 41% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at 10% fair-value upside, at −17%, VIKASLIFE screens richer than that median.

Fair Value models

Bear ₹0.6860 Fair Value ₹0.9660 Bull ₹1.26
Price ₹1.17 · Downside -17.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹0.0630 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ₹32.44 ₹47.71 ₹93.47 77
Growth DCF ₹30.38 ₹50.94 ₹88.95 76
5Y Revenue Exit ₹12.00 ₹16.19 ₹24.07 73
All 17 models by family
DCF Models
FCF DCF ₹32.44 ₹47.71 ₹93.47 77
Owner Earnings ₹2.52 ₹5.55 ₹11.21 71
5Y Revenue Exit ₹12.00 ₹16.19 ₹24.07 73
5Y P/E Exit ₹10.81 ₹15.48 ₹20.41 71
10Y Revenue Exit ₹18.46 ₹28.50 ₹33.68 68
10Y P/E Exit ₹17.78 ₹26.27 ₹38.13 64
Earnings-Based
Graham-Dodd ₹0.6700 ₹4.70 ₹6.59 63
Lynch FV ₹1.59 ₹2.28 ₹2.96 61
PEG = 1.0 ₹1.59 ₹2.28 ₹2.96 57
Multiples
P/E Multiple ₹1.26 ₹1.68 ₹2.11 63
P/S Multiple ₹1.26 ₹1.68 ₹2.11 58
P/B Multiple ₹6.59 ₹8.79 ₹10.98 55
EV/Revenue ₹2.26 ₹3.47 ₹4.68 53
Asset-Based
NCAV (Graham) ₹0.1800 ₹0.2800 ₹0.3500 54
Growth DCF
Growth DCF ₹30.38 ₹50.94 ₹88.95 76
Economic Profit
Residual Income ₹1.96 ₹1.96 ₹2.05 71
Growth Earnings
Growth-Adj P/E ₹1.93 ₹2.76 ₹3.59 67

The fair value above starts from this blend and is adjusted for a cyclical peak year.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 57/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 25
How much profit the company makes from its sales and capital
Quality Growth 44
Are margins and returns getting better?
Cashflow 100
Do the profits arrive as real cash?
Financial strength 49
Debt, balance sheet and risk of trouble
Investment 38
Does it invest with discipline instead of growing at any price?
Low Volatility 74
How calm the share price moves, does not count
Price momentum 18
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+4.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.1%
Start year 2021 (pandemic). Over 10 years: +18.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.0%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+6.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.3%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6.3% vs 38.3%, slowing
Profit margin 2020 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → −11%
Pace: the 5-year rate starts in 2021 (pandemic)

VIKASLIFE screens overvalued: fair value 17% below the price. Compare with Muyuan Foods Group →

Compare Vikas Lifecare Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Farm Products · 297 stocks

Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 57 · Above median
Fair Value upside −17.4% · Below median
Profitability
Return on equity (12 months) 3.4% · Below median
Return on assets 2.4% · Above median
Net margin (12 months) 3.7% · Below median
Operating margin (12 months) −16.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 24.7% · Top 25%
Balance sheet
Debt / equity 0.09× · Below median

Valuation Multiplesvs Farm Products median · lower = cheaper

P/B 0.39× · Cheapest 25%
P/S (12 months) 0.44× · Cheapest 25%
Price / free cash flow (fiscal year) 0.5× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)10 · sector 25
FUTURE (revenue growth)100 · sector 20
PAST (return on equity)14 · sector 17
HEALTH (low debt)95 · sector 94
DIVIDEND (yield)0 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Farm Products stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Charoen Pokphand Foods Public Company CPF 20.10 THB 41.23 THB +105% vs VIKASLIFE
Tyson Foods, Inc TSN $58.82 $73.24 +25% vs VIKASLIFE
Mowi ASA MOWI kr 227.20 kr 273.63 +20% vs VIKASLIFE
Muyuan Foods Group 002714 ¥46.30 ¥53.02 +15% vs VIKASLIFE
United Plantations Berhad 2089 31.42 MYR 34.47 MYR +10% vs VIKASLIFE
Archer-Daniels-Midland Company ADM $72.90 $61.55 −16% vs VIKASLIFE
Wens Foodstuff Group 300498 ¥17.55 ¥12.08 −31% vs VIKASLIFE
Fujian Wanchen Food Group 300972 ¥130.45 ¥88.62 −32% vs VIKASLIFE
Bunge Global SA BG $101.65 $61.59 −39% vs VIKASLIFE
SalMar ASA SALM kr 589.00 kr 260.28 −56% vs VIKASLIFE

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vikas Lifecare Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Vikas Lifecare Limited Fair Value". https://www.fairvalue-calculator.com/stock/VIKASLIFE

Frequently asked questions

Is Vikas Lifecare Limited (VIKASLIFE) overvalued or undervalued?
As of Nov 13, 2026, our model estimates a fair value of ₹0.9660 versus a price of ₹1.17, about 17% lower (overvalued).
What is the fair value of VIKASLIFE?
Our model-based fair value for Vikas Lifecare Limited is ₹0.9660 (as of Nov 13, 2026), built from audited fundamentals. The current price: ₹1.17.
What is the quality score of VIKASLIFE?
Vikas Lifecare Limited has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vikas Lifecare Limited (VIKASLIFE)?
Our model-based price target is the fair value of ₹0.9660 (as of Nov 13, 2026) from 17 valuation models. Cautious scenario ₹0.6860, optimistic scenario ₹1.26. It is a calculation from audited fundamentals, not an analyst target.
What is the Vikas Lifecare Limited stock forecast for 2026?
Our models put fair value at ₹0.9660, about 17% lower versus a price of ₹1.17 (overvalued). Cautious scenario ₹0.6860, optimistic scenario ₹1.26. The calculation is refreshed regularly with new filings.
What is the revenue of Vikas Lifecare Limited (VIKASLIFE)?
Vikas Lifecare Limited reported trailing-twelve-month revenue of about ₹5.0B (latest available figure, as of Nov 13, 2026).
What is the intrinsic value of Vikas Lifecare Limited (VIKASLIFE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vikas Lifecare Limited it is ₹0.9660 per share (as of Nov 13, 2026), against a price of ₹1.17. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Vikas Lifecare Limited stock overvalued or undervalued in 2026?
As of Nov 13, 2026, VIKASLIFE trades above its calculated fair value: price ₹1.17, fair value ₹0.9660, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VIKASLIFE?
No. The price is what the market pays today (₹1.17); the fair value is what the company's own numbers justify (₹0.9660). For Vikas Lifecare Limited the two are ₹0.2040 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vikas Lifecare Limited worth?
The market values Vikas Lifecare Limited at about ₹2.2B (market capitalisation, as of Nov 13, 2026). Per share that is ₹1.17; our models calculate a fair value of ₹0.9660 per share.
What do the bullish and bearish scenarios say about VIKASLIFE?
Our models span a range for Vikas Lifecare Limited: cautious scenario ₹0.6860, base ₹0.9660, optimistic ₹1.26 per share (as of Nov 13, 2026, price ₹1.17). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Vikas Lifecare Limited (VIKASLIFE)?
Balance-sheet figures for Vikas Lifecare Limited (as of Nov 13, 2026): return on equity 3.4%, debt of 0.09 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is VIKASLIFE from its 52-week high?
Vikas Lifecare Limited trades at ₹1.17, about 41% below its 52-week high of ₹1.99 and 10% above the low of ₹1.06 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹0.9660 is for.
Which stocks are comparable to Vikas Lifecare Limited?
From the same area (Consumer Defensive) we also value Muyuan Foods Group, Archer-Daniels-Midland Company, Tyson Foods, Inc, Bunge Global SA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vikas Lifecare Limited stock attractive at the current price?
The data as of Nov 13, 2026: price ₹1.17, calculated fair value ₹0.9660 (−17%), Quality Score 57/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VIKASLIFE calculated?
We run Vikas Lifecare Limited through 17 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹0.9660 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Vikas Lifecare Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vikas Lifecare Limited (VIKASLIFE)?
The closing price on Nov 16, 2026 was ₹1.17. Our model-based fair value is ₹0.9660, about 17% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vikas Lifecare Limited right now?
Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹0.6860 to ₹1.26) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Vikas Lifecare Limited

How large is the market capitalisation of Vikas Lifecare Limited (VIKASLIFE)?
The market capitalisation of Vikas Lifecare Limited is ₹2.2B (≈ $23.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vikas Lifecare Limited (VIKASLIFE)?
The price-to-sales ratio of Vikas Lifecare Limited is 0.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vikas Lifecare Limited (VIKASLIFE)?
Earnings per share at Vikas Lifecare Limited are ₹0.1000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vikas Lifecare Limited (VIKASLIFE)?
The net margin of Vikas Lifecare Limited is 3.7% (last twelve months), excl. one-off gain FY2026 −24.4%. How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vikas Lifecare Limited (VIKASLIFE)?
The return on equity (ROE) of Vikas Lifecare Limited is 3.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vikas Lifecare Limited (VIKASLIFE)?
On an EBIT basis the return on assets of Vikas Lifecare Limited is −0.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vikas Lifecare Limited (VIKASLIFE)?
The operating margin of Vikas Lifecare Limited is −16.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vikas Lifecare Limited (VIKASLIFE)?
Revenue at Vikas Lifecare Limited is growing 24.7% versus a year earlier (3y avg +1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vikas Lifecare Limited (VIKASLIFE)?
Earnings per share at Vikas Lifecare Limited are growing 233% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Vikas Lifecare Limited (VIKASLIFE) generate?
The free cash flow of Vikas Lifecare Limited is ₹4.3B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vikas Lifecare Limited (VIKASLIFE) carry?
The net debt of Vikas Lifecare Limited is ₹1.0B (fiscal year 2026, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Why does Vikas Lifecare Limited meet the fair value rule although the fair value shown is lower?
Peak profit dampened: ₹2.76 → ₹0.9660. The latest annual profit is far above the years before, and such peaks rarely last. So we calculate cautiously with ₹0.9660 instead of ₹2.76. If the profit stays high, we ease the caution year by year. As in the backtest, the fair value rule checks the value before: +136% against the price.
Free · no account needed

Watch Vikas Lifecare Limited in the live analysis

One click puts Vikas Lifecare Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.